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Abstract
Medial vascular calcification (MVC) is common in patients with chronic kidney disease, obesity,
and aging. MVC is an actively regulated process that resembles skeletal mineralization, resulting
from chondro-osteogenic transformation of vascular smooth muscle cells (VSMCs). Here, we used
mineralizing murine VSMCs to study the expression of PHOSPHO1, a phosphatase that
participates in the first step of matrix vesicles-mediated initiation of mineralization during
endochondral ossification. Wild-type (WT) VSMCs cultured under calcifying conditions exhibited
increased Phospho1 gene expression and Phospho1-/- VSMCs failed to mineralize in vitro. Using
natural PHOSPHO1 substrates, potent and specific inhibitors of PHOSPHO1 were identified via
high-throughput screening and mechanistic analysis and two, designated MLS-0390838 and
MLS-0263839, were selected for further analysis. Their effectiveness in preventing VSMC
calcification by targeting PHOSPHO1 function was assessed, alone and in combination with a
potent tissue-nonspecific alkaline phosphatase (TNAP) inhibitor MLS-0038949. PHOSPHO1
inhibition by MLS-0263839 in mineralizing WT cells (cultured with added inorganic phosphate)
reduced calcification in culture to 41.8% ± 2.0 of control. Combined inhibition of PHOSPHO1 by
MLS-0263839 and TNAP by MLS-0038949 significantly reduced calcification to 20.9% ± 0.74 of
control. Furthermore, the dual inhibition strategy affected the expression of several mineralization-
related enzymes while increasing expression of the smooth muscle cell marker Acta2. We
conclude that PHOSPHO1 plays a critical role in VSMC mineralization and that “phosphatase
inhibition” may be a useful therapeutic strategy to reduce MVC.
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INTRODUCTION
Medial vascular calcification (MVC), also known as Monckeberg’s sclerosis, is
characterized by the deposition of hydroxyapatite (HA) crystals within the medial layers of
arteries and is increasingly recognized as an important clinical problem.(1,2) For decades,
calcification of the cardiovascular system was considered an uncommon condition limited to
advanced senile arteriosclerosis. However, its prevalence corresponds roughly with age,
with coronary artery calcification occurring in 20% of young adults, 60% in the middle age
group, and 90% of the elderly.(3) Although vascular calcification is a major contributor to
cardiovascular disease (CVD) and death in patients with chronic kidney disease (CKD),
there is no established treatment for this morbid condition.(4,5)
MVC follows an active endochondral ossification-like process, resulting in the formation of
bone marrow and cartilage.(6,7) The process involves chondro-osteoblastic conversion of
vascular smooth muscle cells (VSMCs),(8,9) evident from the loss of characteristic smooth
muscle cell markers and development of osteoblastic features, such as expression of tissue-
nonspecific alkaline phosphatase (TNAP), osteocalcin (BGLAP) and osteopontin (SPP1),
and osteocyte markers such as sclerostin and podoplanin.(10-14) It has been hypothesized that
phosphate accelerates this chondro-osteogenic conversion by inducing expression of runt-
related transcription factor 2 (RUNX2), osteocalcin and TNAP.(15) Elevated TNAP further
favors vascular calcification by hydrolyzing the calcification suppressor inorganic
pyrophosphate (PPi).(16-19) The importance of PPi has been illustrated in mouse models,
deficient in ectonucleotide pyrophosphatase/phosphodiesterase 1 (Enpp1-/-), or in the PPi-
channeling function of ANK (ank/ank). Both models are characterized by decreased levels
of extracellular PPi, caused by a combination of deficient output and increased degradation
by TNAP, and exhibit a phenotype of hypermineralization.(20) We have shown in Enpp1-/-
mouse that inhibition of TNAP by potent inhibitors can restore PPi to sufficient levels to
maintain normal mineralization.(16)
The phosphatase PHOSPHO1, first identified in the chicken as a member of the haloacid
dehalogenase superfamily of Mg2+-dependent hydrolases,(21-24) is expressed in
chondrocytes in mineralizing cartilage at levels 120-fold higher than in non-mineralizing
tissues.(25) PHOSPHO1 shows high phosphohydrolase activity towards
phosphoethanolamine (P-Etn) and phosphocholine (P-Cho), both of which are key
components of matrix vesicles’ (MVs) phospholipids.(26) Using lansoprazole as a
pharmacological inhibitor of PHOSPHO1, we demonstrated that PHOSPHO1 is present and
active inside chondrocyte- and osteoblast-derived MVs.(25) However, lansoprazole was
identified from the Library of Pharmacologically Active Compounds (LOPAC1280) and, as
expected, inhibits a number of proteins other than PHOSPHO1, including TNAP.(27,28)
More recently, we showed that PHOSPHO1 and TNAP expression coincide during skeletal
mineralization(29) and using single and double knockout mice, we demonstrated that
PHOSPHO1 controls TNAP expression in mineralizing cells and is essential for
mechanically competent mineralization.(30,31) Furthermore, PHOSPHO1/TNAP double
knockout mice show complete absence of skeletal mineralization.(30)
Ultrastructural studies have identified HA-containing MVs in human aorta, which indicates
that these structures may provide the nidus for vascular calcification.(32,33) In this study, we
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provide the first description of the role of PHOSPHO1 in the calcification of VSMCs. We
show that inhibition of PHOSPHO1 activity can reduce calcification in hypermineralizing
wild-type (WT) VSMCs and that the combined use of selective PHOSPHO1 and TNAP
inhibitors considerably reduces calcification in these cells, indicating that “phosphatase
inhibition” constitutes a viable approach for the prevention and treatment of MVC.
MATERIALS and METHODS
Isolation and culture of primary WT, Phospho1-/- and Enpp1-/- VSMCs
Vascular smooth muscle cells (VSMCs) isolated from WT, Enpp1-/- and Phospho1-/- mice
were used for in vitro calcification studies. The VSMCs were isolated from excised aortas
using a collagenase digestion method and the smooth muscle phenotype was confirmed by
RT-PCR analysis for smooth muscle α-actin as before.(16) One mouse aorta provided an
average of 5 × 105 VSMCs. These cells were cultured (in triplicate) at a density of 0.25 ×
105 cells/mL/well in a 24 well plate using α-MEM supplemented with 50 μg/mL ascorbic
acid and 2.5 mmol/L β-glycerophosphate or 3 mmol/L sodium phosphate to induce
calcification. Cells were cultivated in the mineralization media for up to four weeks and
media was changed every second day. Inhibitors were freshly dissolved in dimethylsufoxide
(DMSO) and added at each medium change at a final concentration of 30 μmol/L.
Analysis of gene expression
RNA was extracted using an RNAeasy Plus Kit (Qiagen, Valencia, CA, USA), according to
the manufacturer’s instructions. RNA was reverse transcribed and specific cDNAs were
quantified by real-time PCR using dual-labeled hydrolysis probes (FAM-TAMRA) as
before.(14,30) Primers and probes were obtained from Eurogentec North America (San
Diego, CA, USA) and their sequences are provided in the Data Supplement.
Expression and preparation of test enzymes
A construct for expression of the human bone-specific PHOSPHO1 isoform was generated
by ligating a PCR fragment encoding the bone specific N-terminal 40 amino acids, a partial
fragment of cDNA (Genebank accession BC117187) encoding the common isoform, and a
C-terminal polyhistidine tag into the pCMV-SCRIPT vector. The expression vector was
transfected into HEK293 cells, and recombinant bone isoform PHOSPHO1 protein was
purified by a standard procedure.(26) Soluble epitope-tagged human TNAP and ENPP1 was
produced and purified as described previously.(16)
High-throughput screening
High-throughput screening (HTS) of 55,000 compounds from the MLSMR compound
collection was conducted using a colorimetric assay based on the ability of PHOSPHO1 to
liberate phosphate from P-Etn and its reaction with the Biomol Green reagent (Biomol
International, Plymouth Meeting, PA, USA). HTS provided approximately 5,000
compounds that showed greater than 50% activity in the single point assay, a hit rate of 3%.
Subsequent hit follow up and validation in dose response identified sub-micromolar
inhibitors of PHOSPHO1 (see PubChem BioAssay AID 1666 for details). Initial HTS was
performed in duplicate at a concentration of 20 μmol/L with dose-response assays using a
10-point two-fold serial dilution of the hit compounds in DMSO. Hit confirmation was
performed using the Biomol Green colorimetric assay to verify inhibitory activity against
PHOSPHO1 in dose-response mode. Compounds that were active in dose-response mode
against PHOSPHO1 and soluble in the range relevant to their potency were prioritized for
synthetic chemistry follow-up to increase selectivity against ENPP1 and TNAP and/or
potency against PHOSPHO1.
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Enzyme kinetics
Reactions were measured in triplicate in 96-well plates containing 20 mmol/L MES-NaOH,
pH 6.7, 0.01% (w/v) BSA, 0.0125% (v/v) Tween-20, 2 mmol/L MgCl2, 62.5 μmol/L P-Etn
or P- Cho (Sigma-Aldrich, St. Louis, MO, USA), test compound dissolved in DMSO
(ranging from 0.0143 nmol/L - 300 μmol/L) and 0.3 nmol/L of purified recombinant human
PHOSPHO1, in a total volume of 50 μL. Each reaction contained a final concentration of
1% (v/v) DMSO, which was determined to be insufficient to interfere with PHOSPHO1
activity (data not shown). Enzyme was pre-incubated with the inhibitors and the reaction
was initiated by addition of substrate 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine
(Sigma-Adrich, P-Eth) or phosphocholine chloride calcium salt tetrahydrate (Sigma-Aldrich,
P-Chol) and allowed to proceed for 60 min at room temperature. Reactions were stopped
with 100 μL Biomol Green reagent and absorbance was measured at 620 nm, after which
the inhibitory effect of each compound was calculated as a percentage of control. The IC50
was calculated from plots of residual enzyme activity against inhibitor concentration, using
Origin Scientific plotting software (Northampton, MA, USA). Single point experiments with
inhibitors at 30 μmol/L were performed to test selectivity for PHOSPHO1 inhibition versus
TNAP inhibition, at those concentrations used during VSMC calcification, as described
previously.(16)
The inhibition of recombinant human TNAP, and three TNAP variants (Tyr371Ala,
Glu108Phe and His434Glu), with mutations previously implicated in the active site
positioning of the classic TNAP inhibitor levamisole,(34) by the TNAP inhibitor
MLS-0038949(35) was carried out at pH 7.5, as previously reported.(16) The nature of the
inhibition was investigated using double reciprocal plots of velocity (v) versus substrate
concentration, at various inhibitor concentrations (0-1 μmol/L) and secondary replots.
Likewise, the nature of the inhibition of PHOSPHO1 by the selected inhibitors was
determined via double reciprocal plots of v versus the concentration of P-Etn.
Computer modeling and docking
To complement the kinetic studies on PHOSPHO1 inhibition by both classical inhibitors
such a lansoprazole(25) and the novel inhibitors described here, we modeled the protein and
performed computer docking. Several protein models were obtained using a number of
homology modeling web servers. The PHOSPHO1 protein sequence was extracted from the
NCBI Protein database and submitted for homology modeling using FFAS03,(36)
ITASSER,(37) and SWISSModel.(38) Retrieved models were superposed and regions of high
structural homology (consensus structure) were defined. The mobile regions were examined
and the models were grouped into conformational classes as judged by the RMSD. The
models showed divergence in two areas: two helices and two loops closing the active site.
Structural representatives of at least three classes of models were extracted and used for
docking using the SwissDock server(39) and the program EAdock.(40) A single model of
PHOSPHO1, produced by ITASSER, was selected as all other classes had hindered access
to the active site. Docking was performed using this model with selected PHOSPHO1
inhibitors. One hundred and fifty hits with the highest pseudo-energy were retained in the
search. Subsequently, clustering analysis was performed and the hits were clustered into
spatially matching hits. The representatives of these families show different binding modes
for individual compounds.
Calcification assay
Calcium deposition in cultured VSMCs in the presence or absence of inhibitors was
evaluated by staining cell layers with Alizarin Red, as before.(16) Cells were washed twice
with both PBS and 70% ethanol, then fixed in 100% ethanol for 5 min. Cells were stained
with 2% Alizarin Red (pH 4.2) for 30 min at room temperature and washed with distilled
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water. Alizarin Red-stained cultures were extracted with 10% cetylpyridium chloride for 45
min and A570 nm was measured. The matrix was also decalcified in 0.6 N HCl for 24 hours,
and free calcium was determined colorimetrically using a commercially available kit
(Randox Laboratories, Crumlin, UK), after correction for total protein concentration. The
protein content of the cultures was measured using Bio-Rad protein assay reagent (Bio-Rad
Laboratories, Hertfordshire, UK) based on the Bradford dye procedure, and gamma globulin
was used as a standard (Fig.1 C, D). For experiments of effect of inhibitors on
mineralization of cultured WT, Enpp1-/- and Phospho1-/- VSMCs the cell layers were
stained with Alizarin Red, extracted with 10% cetylpyridium and A570 was measured.
MTT reduction assay for cell viability
Cells were cultivated for 7 days and treated with 30 μmol/L of TNAP and/or PHOSPHO1
inhibitors as described previously. To determine cell viability, the growth medium was
removed and cells were incubated with 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT, Sigma-Aldrich) at a final concentration of 0.5 mg/mL in phenol-
red-free DMEM containing 10% heat-inactivated FBS at 37°C in the dark for 3.5 hours. An
equal volume of the dissolving buffer (22% (w/v) SDS in 0.02 M HCl) was added to the
wells with gentle trituration. Cultures were incubated with the dissolving buffer at 37°C in
the dark for 4 hours. After the dye was completely dissolved, 200 μL of the solution was
transferred to a 96-well plate and absorbance was recorded at 570 nm.
Statistical analysis
All data are expressed as the mean ± S.E.M. Differences in relative RNA expression for
Phospho1 and Alpl in WT VSMCs and for calcium deposition in Phospho1-/- versus WT
VSMCs were analyzed with an unpaired t test with Welch correction and calculation of a
two-tailed p value. Differences in the degree of VSMC calcification and multiple
comparisons of the relative RNA expression data were also analyzed by Student’s t test. The
upregulation of Phospho1 in VSMCs and osteoblasts was analyzed as a function of time by
linear regression analysis. P values less than 0.05 were considered significant. Statistical
tests were performed using Instat 3 (GraphPad, San Diego, CA, USA).
RESULTS
Role of PHOSPHO1 in VSMCs calcification
Phospho1 mRNA expression was measured in WT VSMC cultures, under calcifying
conditions over 28 days and compared to Phospho1 expression in WT calvarial osteoblasts.
In osteoblasts, the normalized Phospho1 expression increased in a linear manner (r2=0.9, p
<0.0001) until day 28 (Fig. 1A). In VSMCs, Phospho1 expression was upregulated and
increased linearly (r2 = 0.881, p <0.0001) until day 21, then plateaued between days 21 and
28 (Fig. 1B). To confirm that PHOSPHO1 is a key enzyme in VSMC mineralization, we
analyzed calcium deposition normalized to the amount of protein in 28 day cultured
Phospho1-/- VSMCs, in comparison to WT control cells. Quantitative (Fig. 1C) and
qualitative (Fig. 1D) analyses of calcium deposition indicated a reduced ability of
Phospho1-/- VSMCs to calcify. We also examined the expression of Phospho1 and Alpl
mRNA in Enpp1-/- VSMCs. The initial 18s-normalized Alpl expression was approximately
10-fold higher in Enpp1-/- VSMCs than in WT after 21 days of culture, in agreement with
our previous observations,(16) while Phospho1 expression in Enpp1-/- VSMCs was slightly
lower than in WT VSMCs (Fig. 1E).
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Selection and properties of PHOSPHO1 and TNAP inhibitors
Because PHOSPHO1 is upregulated in cultures of calcifying WT VSMCs and the known
PHOSPHO1 inhibitor lansoprazole lacks target specificity, development of more specific
PHOSPHO1 inhibitors is necessary to study the effect of PHOSPHO1 inhibition in VSMC
calcification. High throughput screening for PHOSPHO1 inhibitors revealed several potent
hits in the benzoisothiazolone class of compounds, indicating a nascent structure-activity-
relationship (SAR) that would provide traction for inhibitor optimization. The potency and
selectivity of the synthesized compounds were assessed by in vitro enzymatic assays using
purified human PHOSPHO1, TNAP(42) and ENPP1 (see Data Supplement Fig. S1 for the
dose-response curves for the inhibition of PHOSPHO1 by the nine new inhibitors using
PHOSPHO1 natural substrates P-Etn and P-Cho). The IC50 values derived from these plots
are shown in Table 1. MLS-0390838 and MLS-0263839 were the most potent, with IC50
values of 0.13 and 0.14 μmol/L respectively.The mechanism of PHOSPHO1 inhibition was
investigated via double reciprocal plots of PHOSPHO1 activity versus substrate
concentration (32-170 μmol/L), in the presence of various concentrations of inhibitor (0-0.9
μmol/L). Fig. 2 shows how these lines intersect on the y-axis, confirming the competitive
nature of the inhibition for both lansoprazole (Fig. 2A) and MLS-0263839 (Fig. 2B) with Ki
values of 0.16 ± 0.03 μmol/L and 0.22 ± 0.01 μmol/L, respectively. Likewise,
MLS-0390838 was found to inhibit PHOSPHO1 in a competitive manner (not shown).
MLS-0390838 and MLS-0263839 were selected as specific PHOSPHO1 inhibitors, as they
showed minimal cross-inhibition of TNAP (Fig. 3A, B) and no inhibition of ENPP1 activity
(not shown). Figure 3C, D show the specific inhibition of PHOSPHO1 by MLS-0390838
and MLS-0263839 using P-Etn (Fig. 3C) and P-Chol (Fig. D) as substrates.
Inhibition of TNAP has been shown to prevent VSMC calcification.(16) To achieve more
potent TNAP inhibition, new inhibitors were identified.(35) In this study we aimed to
determine whether combined inhibition of both TNAP and PHOSPHO1 was more effective
than inhibition of either enzyme on its own. To accomplish this, we characterized the
previously reported TNAP inhibitor MLS-0038949(35) to evaluate its suitability for
inclusion in combined phosphatase inhibition experiments. MLS-0038949 was able to
inhibit the p-nitrophenylphosphatase (Fig. 3A) (pNPPase) and pyrophosphatase (PPiase)
activities of TNAP (Fig. 3B). Conversely, Fig. 3C and D shows that this compound
selectively inhibits TNAP, but not PHOSPHO1. We also studied the mechanism of TNAP
inactivation by MLS-0038949 at pH 9.8 (not shown) and pH 7.5 (Fig. 4) as described
before.(16) The parallel lines (Fig. 4A) indicate that TNAP is inhibited by MLS-0038949 in
an uncompetitive manner, both at pH 7.5 and at pH 9.8 (not shown). Secondary re-plots of
the y-axis intercepts allow derivation of the corresponding inhibition constant, which was
calculated as Ki = 0.32 ± 0.04 μmol/L at pH 7.5 and 0.74 ± 0.01 μmol/L at pH 9.8. The
active site positioning of MLS-0038949 (Fig. 4B) was investigated in inhibition studies with
TNAP mutants implicated in the active site positioning of the classic TNAP inhibitor
levamisole(36) (Glu108Phe, Tyr371Ala and His434Glu) and compared to inhibition by the
reference compound levamisole (Fig. 4C). These analyses revealed that, similar to
levamisole, MLS-0038949 positioning in the TNAP active site depends primarily on the
active site residues Tyr371 and His434, which are important for TNAP function and for the
stabilization of uncompetitive inhibitors levamisole and theophylline.(34) Correspondingly,
the Ki values for the inhibition of TNAP by MLS-0038949 at pH 7.5 were 0.13 ± 0.02
μmol/L (Glu108Phe), 4.1 ± 0.5 μmol/L (Tyr371Ala), and 20 ± 1.7 μmol/L (His434Glu).
In silico docking of inhibitors in the active site
A model of PHOSPHO1 produced by ITASSER displayed the best features for molecular
docking and was used for further studies. The model showed an organized tertiary structure
with well-packed external helices surrounding the beta-pleated core of the protein. The
Kiffer-Moreira et al. Page 6
J Bone Miner Res. Author manuscript; available in PMC 2014 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
active site, identified by homology to mouse 5’-nucleotidase III (Protein Data Bank ID
2bdu) and phosphoserine phosphatase from Helicobacter pylori (Protein Data Bank ID
3m1y) was located deep in the protein matrix and was surrounded by two helices with two
loops closing the site. The metal ion was modeled into the active site as suggested by the
presence of homologous carboxylate bearing groups (Asp and Glu). Docking carried out in
SwissDock with three compounds (lansoprazole, MLS-0263839, MLS-0390838) produced
150 top scoring hits for each. Clustering analysis identified 19 clusters (docking poses) for
lansoprazole, 6 clusters for MLS-0263839 and 17 clusters for MLS-0390838. Analysis of all
clusters showed different binding modes for individual compounds in reference to the three-
dimensional location of the active site. Only a single cluster for lansoprazole and
MLS-0390838 was not located in the active site pocket. The rest of the clusters were
blocking the entry to the metal ion-binding pocket, although none of the compounds had a
direct contact with a metal ion, consistent with the competitive nature of these inhibitors.
For visualization purposes, a single representative of every compound with the best pseudo-
energy score was selected. The pseudo-energy of these representatives corresponds with the
physiological effect and affinity of the compounds to PHOSPHO1. The highest pseudo-
energy was shown by MLS-0390838 (30 kcal/mol), followed by MLS-0263839 (25 kcal/
mol) and lansoprazole (15 kcal/mol). Fig. 5A shows a comparison of docking poses for the
lowest energy representatives of lansoprazole, MLS-0390838 and MLS-0263839 in the
PHOSPHO1 active site. In this model MLS-0390838 and MLS-0263839 do not penetrate
deeply into the active site pocket and do not interact with the catalytic site metal ion.
Likewise, Fig. 5B shows MLS-0038949 docked in the TNAP active site. Docking of this
uncompetitive TNAP inhibitor indicates a preferred interaction with active site residue
His434, consistent with the kinetic data.
Inhibition of in vitro VSMC calcification and its effect in relative mRNA expression
The effect of the PHOSPHO1 and TNAP inhibitors on calcification of WT, Enpp1-/- and
Phospho1-/- VSMCs was investigated. Toxicity of the inhibitors in 7 day cultures of WT
VSMCs was excluded by MTT test (see Data Supplement Fig. S2). The MTT test was not
successful in 21-day cultures because of the more extensive mineral content (not shown).
Quantification of Alizarin Red staining of WT VSMCs cultivated for 21 days in the
presence of inorganic phosphate (Pi) (Fig. 6A) or β-glycerophosphate (β-GP) (Fig. 6B)
shows that MLS-0263839 was able to reduce mineralization to 41.8% ± 2.0 and 53.8% ±
4.1, respectively, relative to vehicle-treated control cells. The TNAP inhibitor
(MLS-0038949) reduced Alizarin Red staining to54.4% ± 3.6 of the value for vehicle-
treated WT VSMCs cultured in the presence of Pi and 62.1% ± 9.9 for WT VSMCs
cultivated in the presence of β-GP, reinforcing the involvement of TNAP in vascular
calcification (16). Combined inhibition of both enzymes reduced calcification in Pi- and β-
GP-containing media significantly further than inhibition of either inhibitor alone.
Mineralization was reduced to 20.9% ± 0.74 (Fig. 6B) and 34.5% ± 0.78 (Fig. 6C) of the
control by the MLS-0263839/MLS-0038949 combination in VSMCs cultured with Pi and β-
GP, respectively. Lansoprazole alone and/or in combination with MLS-0038949 also
significantly inhibited mineralization. The combination of the two PHOSPHO1 inhibitors,
MLS-0026839 and lansoprazole was toxic to the cells (see Data Supplement Fig. S2). The
effect of the inhibitors MLS-0038949, MLS-0263839 and combination MLS-0038949/
MLS-0263839 were also investigated in Enpp1-/- and Phospho1-/- VSMCs. In Enpp1-/-
VSMCs, both inhibitors strongly reduced mineralization and the combination
MLS-0038949/MLS-0263839 essentially abolished in vitro mineralization in Enpp1-/- (Fig.
6C). As expected, in Phospho1-/- VSMCs, only the TNAP inhibitor MLS-0038949
significantly inhibited mineralization (Fig. 6D).
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WT cells cultivated under the same conditions as described in Fig. 6B were analyzed for
differences in the mRNA expression of key enzymes involved in mineralization as well as
osteogenic and VSMC markers. Fig. 7 shows the effect of inhibitor treatment on the
expression of osteogenic markers such as Alpl, Runx2, Spp1, Bglap and Col1a1. Fig. 7A
shows that the combination of PHOSPHO1 and TNAP inhibitors significantly decreased the
expression of Alpl mRNA (p<0.05) whereas the expression of Enpp1 increased (p<0.01,
Fig. 7B). The expression of Phospho1 mRNA was not significantly different compared to
the DMSO control cells in any of the treatments (Fig. 7C). Dual inhibitor treatment did not
affect mRNA levels of the osteogenic markers Runx2, Opn and Ocn (Fig. 7D, E, F), but the
expression of Col1a1 was strongly decreased (p<0.01, Fig. 7G). In contrast, dual inhibition
strongly raised expression of the VSMC marker Acta2 (Fig. 7H).
DISCUSSION
The pathological mechanisms underlying medial vascular calcification are incompletely
understood. It is known that MVC involves the loss of calcification suppressors, such as
extracellular inorganic pyrophosphate (ePPi).(43,44) We have shown previously that Enpp1-/-
and ank/ank mice display equivalent reductions in plasma ePPi concentrations(19,20) and
both animal models develop comparable soft-tissue calcifications, including MVC
accompanied by upregulation of TNAP expression in their VSMCs.(16) Furthermore, we
have documented that MVC in the uremic rat, a model of end-stage renal disease, is
accompanied by an increase in the expression of TNAP, a key enzyme in PPi
metabolism.(17) MVC resulting from NT5E deficiency also appears to be caused by elevated
expression of TNAP.(45)
More recently, the role of another phosphatase, PHOSPHO1, in calcification has been
established. This enzyme is crucial for initiation of skeletal mineralization (30) and
mechanically competent mineralization (31), and is found inside MVs in calcifying
tissues.(23,25) PHOSPHO1has been proposed to scavenge Pi from phospholipids inside the
MV to generate a Pi/PPi ratio conducive to calcification, whereas TNAP acts later in the
mineralization process by restricting extracellular PPi. Phospho1-/- mice display a distinct
phenotype, with growth plate abnormalities, spontaneous fractures, bowed long bones,
osteomalacia and scoliosis.(30) Consistent with the non-redundant functions of these two
enzymes, transgenic over-expression of TNAP does not correct the bone phenotype in
Phospho1-/- mice.(30) Furthermore, TNAP/PHOSPHO1 double knockout mice exhibit a
phenotype more severe than those of the respective single knockouts: complete absence of
skeletal mineralization. The importance of PHOSPHO1 in skeletal mineralization combined
with the knowledge that MVC also appears to proceed via chondro-osteogenic
differentiation of VSMCs and MV-mediated calcification (32,33), suggest that PHOSPHO1
might have a functional role in MVC and could serve as a therapeutic target. Here, we
provide the first evidence that PHOSPHO1 is involved in MVC, as Phospho1 expression
increased in calcifying WT VSMCs and calcification was impaired in Phospho1-/- VSMCs.
Inhibitors of PHOSPHO1 identified from the small LOPAC1280 library of
pharmacologically active compounds (lansoprazole, ebselen and SCH-202676), showed that
inhibiting PHOSPHO1 function further impaired both the mineralization ability of MVs
from TNAP null osteoblasts and skeletal mineralization of developing chick long
bones.(25,29) Lansoprazole was previously reported to be specific for PHOSPHO1, but
Ciancaglini et al. (2010) showed it partially inhibits ENPP1 and TNAP activity. (25,42) We
also observed in the mineralization studies that lansoprazole showed toxicity to smooth
muscle cells and that lansoprazole inhibited mineralization in Phospho1-/- chondrocytes (not
shown), confirming its off-target effects. The HTS performed in this study provided two
compounds (MLS-00390838 and MLS-0263839), superior to lansoprazole. These inhibitors
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are highly selective for PHOSPHO1, with no detectable cross-inhibition of TNAP or
ENPP1. MLS-00390838 and MLS-0263839 appeared to stabilize at several docking points
inside the PHOSPHO1 active site, corroborating inhibitor selectivity. Both inhibitors act
competitively, with sufficient affinity and selectivity to evaluate them as PHOSPHO1
inhibitors in VSMC calcification.
The finding that TNAP upregulation is a common phenomenon at sites of medial
calcification in several disease models(16, 17, 45) has important translational implications and
has motivated the development of potent inhibitors of the pyrophosphatase activity of TNAP
to prevent and reverse MVC.(16, 35, 46-49) Selective inhibition of TNAP restores ePPi
concentrations to levels high enough to prevent aberrant mineralization(16,35,47). To compare
the relative merits of PHOSPHO1 and TNAP inhibition, we characterized the TNAP
inhibitor, MLS-0038949, for use in mineralization assays. MLS-0038949 is highly specific
for TNAP and does not cross-inhibit PHOSPHO1 or ENPP1.(35) MLS-0038949 is an
uncompetitive TNAP inhibitor, stabilized in the active site by residues H434 and Y371.(17)
When VSMCs were cultured for 21 days in the presence of the PHOSPHO1 or TNAP
inhibitors, PHOSPHO1 inhibition was more effective at preventing calcification than TNAP
inhibition. This enhanced effect may be due to the earlier action of PHOSPHO1 that affects
the intravesicular generation of HA seed crystals during MV-mediated calcification.(30) In
addition, in complete agreement with the genetic data where ablation of Phospho1 gene
functions leads to dowregulation of Alpl gene expression,(30) we observe that the
pharmacological inhibition of PHOSPHO1 leads to downregulation of Alpl mRNA. Thus,
PHOSPHO1 appears to be a good target because not only is initiation of mineralization
suppressed by the direct action of the inhibitor on PHOSPHO1 activity, but it also acts
downstream by downregulating the amount of TNAP activity. Finally, the combined effect
of both types of enzyme inhibitor suppressed VSMC calcification more than each inhibitor
separately, both in WT and Enpp1-/- VSMCs. Interestingly, while double inhibition
essentially abolished mineralization in Enpp1-/- VSMCs (by 93.2% ± 0.2, Fig. 6B), the
effect was less pronounced in WT cells (65.5%± 0.7, Fig. 6C). This discrepancy may be
accounted for by an increased Enpp1 expression in WT cells, in response to double
inhibition treatment (Fig. 7B), since it has been proposed that ENPP1 can act as a backup
pyrophosphatase in the absence of TNAP and maintain the levels of calcification.(30) Thus,
the enhanced inhibition seen in Enpp1-/- cells may be related to the absence of this
compensatory mechanism. This effect was also observed by Villa-Bellosta et al., using
inhibitors in WT aortic ring cultures, (18) who found that TNAP inhibition reduced PPi
hydrolysis by approximately 50%,while the remaining hydrolysis was inhibited by the
ENPP1 inhibitors α,β-methylene ATP and γ,β-α,β-methylene ATP.
MVC involves transdifferentiation of VSMCs into osteochondrogenic-like cells and
consequent matrix mineralization. Here, we measured the effect of phosphatase inhibitors on
the expression of various markers of these processes. We observed no significant difference
in the expression of the osteochondrogenic markers Runx2, osteocalcin (Bglap) and
osteopontin (Spp1) although expression of Col1a1 was markedly impaired by the inhibitors,
both alone and in combination. This indicates that phosphatase inhibition does not affect the
chondro-osteogenic conversion of VSMCs, but prevents deposition of a matrix on which
calcification can occur. While increased TNAP expression is also a marker of VSMC
transdifferentiation, it was significantly downregulated in cultures containing the
PHOSPHO1 inhibitor. This discrepancy can be explained by our previous work, which has
shown that PHOSPHO1 knockout mice have reduced TNAP expression and activity. (30)
MVC is also traditionally accompanied by loss of VSMC cell markers. Neither class of
inhibitor alone affected expression of the VSMC gene Acta2, however it was significantly
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higher in the combined inhibitor cultures, indicating that this treatment protected against loss
of VSMCs features.
In conclusion, this paper shows that at least two phosphatases are implicated in VSMC
calcification, and that combined phosphatase inhibition offers a promising approach for
developing compounds to prevent or attenuate MVC. However, it is important to note that
this strategy may interfere with normal bone formation both by interfering with the
intravesicular initiation of HA seed crystal deposition mediated by PHOSPHO1 function as
well as by interfering with extravesicular propagation of HA crystal deposition as a result of
raising PPi levels resulting from TNAP downregulation and inhibition and future work will
need to address this potentially significant concern. Furthermore, study of selective
inhibitors in cultured VSMCs also provides us with new insights about how the enzymes
TNAP, PHOSPHO1 and ENPP1 interact during VSMC mineralization. We are currently
using the scaffolds described here to design drug-like compounds for in vivo testing and
further investigate the potential of PHOSPHO1 inhibitors as a potential treatment for MVC.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Expression of Phospho1 in VSMCs and its role in VSMC mineralization
Normalized Phospho1 mRNA expression as a function of the calcification time in cultured
WT murine (A) calvarial osteoblasts and (B) aortic VSMCs. (C) Calcium deposition in WT
and Phospho1-/- murine aortic VSMCs after 28 days of culture. (D) Alizarin Red staining of
WT and Phospho1-/- murine aortic VSMCs after 28 days of culture. (E) Normalized
Phospho1 and Alpl expression in Enpp1-/- aortic VSMCs versus WT VSMCs, after 21 days
in culture under mineralizing conditions. Results are presented as mean ± S.E.M. (*p < 0.05,
**p < 0.01, ***p < 0.001).
Kiffer-Moreira et al. Page 14
J Bone Miner Res. Author manuscript; available in PMC 2014 January 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 2. Mode of action of PHOSPHO1 inhibition by lansoprazole and MLS-0263839
Double reciprocal plots of PHOSPHO1 activity versus the concentration of the PHOSPHO1
substrate P-Etn (32 – 170 μmol/L), in the presence of increasing concentrations of
lansoprazole (A) and MLS-0263839 (B). Results are presented as mean ± S.E.M.
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Fig. 3. Selectivity of PHOSPHO1 and TNAP inhibitors
Point experiments with the PHOSPHO1 inhibitors MLS-0390838 and MLS-0263939 and
TNAP inhibitor MLS-0038949 at 0 (100% control, open bar), 1 (light gray bars), 10 (dark
gray bars) and 30 (black bars) μmol/L, illustrating specificity during hydrolysis by TNAP of
the substrates pNPP (A, 10 mmol/L Pnpp in 50 mmol/L Tris-HCl buffer, pH 7.5, containing
1 mmol/L MgCl2, 20 μmol/L zinc acetate) and PPi (B, 60 μmol/L PPi in 50 mmol/L Tris-
HCl buffer, pH 7.5, containing 1 mmol/L MgCl2, 20 μmol/L ZnAc), and by PHOSPHO1 for
the substrates P-Etn (C, 62.5 μmol/L P-Etn in 20 mmol/L MES-NaOH, pH 6.7, 0.01% (w/v)
BSA, 0.0125% (v/v) Tween 20, 2 mmol/L MgCl2) and P-Cho (D, 62.5 μmol/L P-Cho in
MES-NaOH, pH 6.7, 0.01% (w/v) BSA, 0.0125% (v/v) Tween 20, 2 mmol/L MgCl2).
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Fig. 4. Mode of action of TNAP inhibition by MLS-0038949
Double reciprocal plots of TNAP activity versus the concentration of the TNAP substrate
pNPP (0.055 – 1 mmol/L) at pH 7.4, in the presence of increasing concentrations of
MLS-0038949 and re-plot of the y-intercepts versus the concentration of MLS-0038949 (A).
Residual TNAP activity during dose-dependent inhibition by MLS-0038949 (B) and
levamisole (C) of hTNAP and its three active site mutants (Tyr371Ala, Glu108Phe and
His434Glu).
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Fig. 5. Modeling of docked PHOSPHO1 and TNAP inhibitors
Computer docking of PHOSPHO1 inhibitors MLS-0263839 (in blue) and MLS-0390838 (in
purple) in comparison to lansoprazole (in yellow) into the active site of the modeled
structure of PHOSPHO1 (A) and of the potent uncompetitive TNAP inhibitor MLS-0038949
(in blue) in the active site of the modeled structure of TNAP (B). Insets: close-up views of
binding inhibitors.
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Fig. 6. Inhibition of matrix mineralization
Alizarin Red-staining (A570 nm) of 21 day cultures of WT VSMC in the presence of
inorganic phosphate (A) and in the presence of β-glycerophosphate for WT (B), Enpp1-/-
(C) and Phospho1-/- (D) VSMCs. The cells were cultured with 30 μmol/L of the TNAP
inhibitor MLS-0038949 and the PHOSPHO1 inhibitors lansoprazole and MLS-0263839,
either alone or combined, as indicated. Calcium deposition in 21-day VSMC cultures was
evaluated by staining cell layers with Alizarin Red.
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Fig. 7. Gene expression changes in WT VSMCs treated with inhibitors
WT VSMCs were cultured for 21 days in the presence of TNAP inhibitor MLS-0038949 or
PHOSPHO1 inhibitor MLS-0263839, either alone or combination, as indicated. The mRNA
expression was determined by qPCR for Alpl (A), Ennp1 (B), Phospho1 (C), Runx2 (D),
Spp1 (E), Bglap (F), Col1a1 (G), and Acta2 (H).
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Table
IC50 values for PHOSPHO1 inhibitors, using the physiological substrates P-Etn and Pcho.
Compound P-Etn IC50 (μmol/L) P-Cho IC50 (μmol/L)
MLS-0437435.001 1.90 ± 0.15 1.98 ± 0.30
MLS-0437436.001 0.39 ± 0.04 0.49 ± 0.05
MLS-0437437.001 11.20 ± 1.20 10.50 ±0.60
MLS-0437438.001 5.90 ±0.08 4.10 ±0.03
MLS-0437439.001 0.90 ±0.15 0.60 ±0.12
MLS-0390837 1.20 ±0.19 1.20 ±0.17
MLS-0390838 0.13 ±0.01 0.16 ±0.02
MLS-0263839 0.14 ± 0.03 0.24 ± 0.06
MLS-0315922 0.20 ± 0.01 0.24 ± 0.02
Lansoprazole 0.07 ± 0.01 0.06 ± 0.01
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